Brokerages Set Cencora, Inc. (NYSE:COR) PT at $399.00

Shares of Cencora, Inc. (NYSE:COR) have received an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $399.00.

Several equities analysts recently commented on the company. Bank of America dropped their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Wells Fargo & Company upped their price target on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Evercore decreased their price objective on Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Robert W. Baird set a $415.00 price objective on Cencora in a research note on Tuesday, January 13th. Finally, TD Cowen increased their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th.

Cencora Price Performance

COR opened at $364.80 on Wednesday. Cencora has a fifty-two week low of $244.97 and a fifty-two week high of $377.54. The firm has a 50-day moving average of $350.19 and a 200 day moving average of $332.57. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The firm has a market cap of $70.96 billion, a P/E ratio of 43.85, a PEG ratio of 1.71 and a beta of 0.68.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. During the same period in the previous year, the company earned $3.73 earnings per share. The company’s quarterly revenue was up 5.5% on a year-over-year basis. On average, research analysts expect that Cencora will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. This trade represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 15,220 shares of company stock valued at $5,282,867 in the last 90 days. 0.38% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cencora

Hedge funds and other institutional investors have recently modified their holdings of the stock. Atlantic Edge Private Wealth Management LLC grew its stake in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in Cencora in the 4th quarter valued at $25,000. Oakworth Capital Inc. purchased a new position in shares of Cencora during the 4th quarter valued at $26,000. Elyxium Wealth LLC bought a new position in shares of Cencora in the fourth quarter worth $27,000. Finally, Archer Investment Corp increased its holdings in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.